In humans, SGLT-2 inhibitors are used in the treatment of type 2 diabetes, and have been shown consistently to reduce blood glucose concentrations and improve insulin sensitivity without causing hypoglycemia [18,19]. Here, SLC5A2 is linked to type 2 diabetes mellitus.